Company intelligence / Profile preview

VIA Pharmaceuticals, Inc.

San Francisco, California, United Statesviapharma.lt ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

VIA Pharmaceuticals was a biotechnology company focused on developing small molecule drugs for cardiovascular diseases by targeting chronic vascular inflammation. Its lead compound, VIA‑2291, aimed to reduce atherosclerotic plaque inflammation—a key factor in atherosclerosis. The company used proprietary screening systems and technologies such as biomarker measurement and medical imaging for early proof-of-concept. The company merged with Coratus Genetics in 2007 but has since ceased operations.

Therapeutic areas: Metabolic DisordersCardiovascular
Modalities: small molecules
Industry: Biotech

Beyond the preview

Go deeper on VIA Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIA Pharmaceuticals, Inc..

Explore the full profile